Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: a randomized crossover trial in Santiago, Chile

Adverse Reactions/Side Effects The following important adverse reactions are described below and elsewhere in the labeling: Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis [see Warnings and Precautions (5.1)] Volume Depletion [see Warnings and Precautions (5.2)] Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fourniers Gangrene), and Genital Mycotic Infections [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions (5.4)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice

The warning says: If a product is being offered for personal use, injection, or consumption, it is being supplied unlawfully. Legislation and monitoring adapting at pace Whetham says, Peptide regulation in Australia is not static
Broadening use beyond diabetes in tackling comorbidities Perhaps most transformative is that GLP-1 therapies are no longer confined to diabetes alone